Found: 8
Select item for more details and to access through your institution.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 2, p. 369, doi. 10.1007/s10549-021-06197-5
- By:
- Publication type:
- Article
Are aggressive epithelial cancers 'a disease' of Eutherian mammals?
- Published in:
- Ecancermedicalscience, 2018, v. 12, n. 819-843, p. 1, doi. 10.3332/ecancer.2018.840
- By:
- Publication type:
- Article
Oncology Basics Part II. Targeted Therapies.
- Published in:
- AMWA Journal: American Medical Writers Association Journal, 2007, v. 22, n. 1, p. 22
- By:
- Publication type:
- Article
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 5, p. 1217, doi. 10.1007/s00277-019-03639-5
- By:
- Publication type:
- Article
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
- Published in:
- 2010
- By:
- Publication type:
- journal article